Virios Therapeutics shares are trading lower. The company announced data demonstrating improvement in multiple Long-Covid symptoms following treatment with a combination of Valacyclovir and Celecoxib in an exploratory, open-label, proof of concept study.
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics announced data showing improvement in multiple Long-Covid symptoms following treatment with a combination of Valacyclovir and Celecoxib in a proof of concept study. However, the company's shares are trading lower.
July 17, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Virios Therapeutics' shares are trading lower despite the company announcing positive data from a proof of concept study on Long-Covid treatment.
The company's shares are trading lower despite the announcement of positive data from a proof of concept study. This could be due to a variety of factors, including market sentiment, overall market conditions, or investor perceptions about the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100